How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography

    Closed for comments This consultation ended on at   Request commenting lead permission

    5 Recommendations for further research

    5.1 A patient experience study is recommended to better understand the range and severity of side effects and complications from QAngio XA 3D quantitative flow ratio (QAngio QFR), CAAS vessel fractional flow reserve (vFFR), FFR and instantaneous wave-free ratio.

    5.2 Further research is recommended on test failure rates of QAngio QFR and CAAS vFFR and how these affect clinical decision making for revascularisation in clinical practice.

    5.3 Outcome studies are needed to understand the clinical benefit of using QAngio QFR and CAAS vFFR (see section 4.7). These include rates of major adverse cardiovascular events, mortality and EQ-5D data to assess the effect on quality of life.

    5.4 More diagnostic accuracy studies are needed for CAAS vFFR against an appropriate reference standard.